1
|
Mangkalamanee O, Rotcheewaphan S, Phuensan P, Ponpinit T, Hemachudha T, Torvorapanit P. The first human case report of molecularly confirmed co-infection of Brucella melitensis and Coxiella burnetii: A case report. Heliyon 2024; 10:e29685. [PMID: 38681594 PMCID: PMC11053185 DOI: 10.1016/j.heliyon.2024.e29685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2023] [Revised: 04/10/2024] [Accepted: 04/12/2024] [Indexed: 05/01/2024] Open
Abstract
Co-infection with Brucella melitensis and Coxiella burnetii has been rarely reported. To date, there are only two co-infection case reports from Croatia and China which diagnosed the infections mainly through the use of serological tests. In this report, we present the first case of molecularly confirmed B. melitensis bacteremia and C. burnetii spondylodiscitis co-infection in a goat dairy farmer who presented with lumbosacral spondylodiscitis and bilateral psoas abscesses. From the blood culture, B. melitensis was identified by using 16S rRNA gene sequencing and specific PCR. Lumbar bone tissue was found to be positive for C. burnetii using multiplex real-time PCR and was confirmed with a positive result from conventional PCR which detected the infection through the identification of the IS1111 gene. The patient's condition improved after decompressive laminectomy was performed and administration of antibiotics regimen: intravenous gentamicin, oral rifampicin, and oral doxycycline. From our case, it is important to raise awareness of this underreported co-infection with multiple zoonotic diseases, especially Q fever and brucellosis, which share the same exposure risk. Moreover, we also emphasize the use of advanced molecular techniques to improve the diagnostic efficiency and reduce the use of time-consuming procedures among patients who are continuously exposed to such risk factors in areas with high seroprevalence of these zoonotic diseases.
Collapse
Affiliation(s)
- Onjira Mangkalamanee
- Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, Chulalongkorn University, And King Chulalongkorn Memorial Hospital, Thai Red Cross Society, 1873, Rama IV Road, Pathum Wan, Bangkok, 10330, Thailand
| | - Suwatchareeporn Rotcheewaphan
- Department of Microbiology, Faculty of Medicine, Chulalongkorn University, 1873, Rama IV Road, Pathum Wan, Bangkok, 10330, Thailand
- Center of Excellence of Antimicrobial Stewardship, Chulalongkorn University, 1873, Rama IV Road, Pathum Wan, Bangkok, 10330, Thailand
| | - Pawat Phuensan
- Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, Chulalongkorn University, And King Chulalongkorn Memorial Hospital, Thai Red Cross Society, 1873, Rama IV Road, Pathum Wan, Bangkok, 10330, Thailand
- Division of Hospital and Ambulatory Medicine, Department of Medicine, Faculty of Medicine, Chulalongkorn University, And King Chulalongkorn Memorial Hospital, Thai Red Cross Society, 1873, Rama IV Road, Pathum Wan, Bangkok, 10330, Thailand
| | - Teerada Ponpinit
- Thai Red Cross Emerging Infectious Diseases Health Science Centre, World Health Organization Collaborating Centre for Research and Training on Viral Zoonoses, King Chulalongkorn Memorial Hospital-The Thai Red Cross Society, Bangkok 10330, Thailand
| | - Thiravat Hemachudha
- Thai Red Cross Emerging Infectious Diseases Health Science Centre, World Health Organization Collaborating Centre for Research and Training on Viral Zoonoses, King Chulalongkorn Memorial Hospital-The Thai Red Cross Society, Bangkok 10330, Thailand
- Division of Neurology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
| | - Pattama Torvorapanit
- Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, Chulalongkorn University, And King Chulalongkorn Memorial Hospital, Thai Red Cross Society, 1873, Rama IV Road, Pathum Wan, Bangkok, 10330, Thailand
- Emerging Infectious Diseases Clinical Center, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, 1873, Rama IV Road, Pathum Wan, Bangkok, 10330, Thailand
| |
Collapse
|
2
|
Phuensan P, Sirimongkolkasem J, Tantawichien T, Phannajit J, Kerr SJ, Hansasuta P, Chantharit P, Wongsa A, Fuengfoo P, Chittinandana A, Vareesangthip K, Chayakulkeeree M, Jangsirikul S, Schmidt A, Wanvimonsuk K, Winichakoon P, Kajeekul R, Prayoonwiwat W, Rerknimitr R. Immunogenicity and safety of heterologous versus homologous prime-boost schedules with inactivated and adenoviral vectored SARS-CoV-2 vaccines - A prospective multi-center study. Heliyon 2024; 10:e23246. [PMID: 38163241 PMCID: PMC10756999 DOI: 10.1016/j.heliyon.2023.e23246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2023] [Revised: 11/22/2023] [Accepted: 11/29/2023] [Indexed: 01/03/2024] Open
Abstract
Background During the peak of Coronavirus disease (COVID-19) pandemic in Thailand when the emergence of delta variant reduced the efficacy of inactivated vaccine, Thailand had abundance of inactivated vaccine but mRNA vaccine was not available and the supply of adenoviral-vectored vaccine was limited. The heterologous vaccination using CoronaVac and ChAdOx1-nCoV-19 vaccines was applied. We aim to compare the immunogenicity of immune response of primary vaccination with homologous ChAdOx1 nCoV-19 and heterologous vaccination with CoronaVac and ChAdOx1 nCoV-19. Methods A total of 430 adults, scheduled to receive ChAdOx1-nCoV-19 as their second dose of primary COVID-19 vaccination, were enrolled. Participants were classified into two groups based on the first dose vaccine as CoronaVac (heterologous group) or ChAdOx1 nCoV-19 (homologous group). The primary outcome was antibodies to the SARS-CoV-2 spike protein receptor binding domain (anti-RBD) titres at 28 days after the second dose of vaccination. Secondary outcomes were anti-RBD titres at 90 days, surrogate viral neutralizing test (sVNT) at 28 and 90 days, and adverse events. Findings In 358 participants with correct vaccine interval, the anti-RBD geometric mean titre ratio for the heterologous versus homologous group was 0.55 (95%CI; 0.44-0.067); p < 0.001 at day 28, and 0.80 (95%CI; 0.65-1.00); P = 0.05 at day 90. Median sVNT neutralizing activity was not significantly different in the heterologous versus homologous group at 28 days (93.5 vs 92.7 %); p = 0.13, but significantly higher in the heterologous group at day 90 (82.9 vs 76.4 %); p = 0.01. Interpretation The homologous vaccination resulted in higher anti-RBD titres at 28 days after vaccination, but titres in the homologous group showed more rapid decline at 90 days. In the sVNT assay, median neutralization was similar at 28 days, but was longer-lasting and higher in the heterologous group at 90 days. Funding This research received funding from the Royal College of Physicians of Thailand special grant 2021 for research initiative during COVID-19 pandemic.
Collapse
Affiliation(s)
- Pawat Phuensan
- Division of Hospital and Ambulatory Medicine, Department of Medicine, King Chulalongkorn Memorial Hospital, Thai Red Cross Society and Faculty of Medicine, Chulalongkorn University, Thailand
- Division of Infectious Diseases, Department of Medicine, King Chulalongkorn Memorial Hospital, Thai Red Cross Society and Faculty of Medicine, Chulalongkorn University, Thailand
| | - Jarongkorn Sirimongkolkasem
- Division of Hospital and Ambulatory Medicine, Department of Medicine, King Chulalongkorn Memorial Hospital, Thai Red Cross Society and Faculty of Medicine, Chulalongkorn University, Thailand
- Division of Gastroenterology, Department of Medicine, King Chulalongkorn Memorial Hospital, Thai Red Cross Society and Faculty of Medicine, Chulalongkorn University, Thailand
| | - Terapong Tantawichien
- Division of Infectious Diseases, Department of Medicine, King Chulalongkorn Memorial Hospital, Thai Red Cross Society and Faculty of Medicine, Chulalongkorn University, Thailand
| | - Jeerath Phannajit
- Division of Clinical Epidemiology, Department of Medicine, King Chulalongkorn Memorial Hospital, Thailand
| | - Stephen J. Kerr
- Department of Research Affairs, Faculty of Medicine, Chulalongkorn University, Thailand
| | - Pokrath Hansasuta
- Division of Virology, Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Thailand
| | - Prawat Chantharit
- Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Thailand
| | - Adisorn Wongsa
- Division of Pulmonary and Critical Care, Department of Medicine, Phramongkutklao Hospital, Thailand
| | - Pusit Fuengfoo
- Department of Surgery, Phramongkutklao Hospital, Thailand
| | - Anutra Chittinandana
- Division of Nephrology, Department of Medicine, Bhumibol Adulyadej Hospital, Thailand
| | - Kriengsak Vareesangthip
- Renal Division, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
| | - Methee Chayakulkeeree
- Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Thailand
| | - Sureeporn Jangsirikul
- Division of Gastroenterology, Department of Medicine, King Chulalongkorn Memorial Hospital, Thai Red Cross Society and Faculty of Medicine, Chulalongkorn University, Thailand
- Gastroenterology and Liver Center, MedPark Hospital, Thailand
| | - Araya Schmidt
- Gastroenterology and Liver Center, MedPark Hospital, Thailand
| | - Kanyika Wanvimonsuk
- Department of Trauma and Emergency Medicine, Royal Thai Airforce Hospital (Sikan), Thailand
| | - Poramed Winichakoon
- Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Thailand
| | - Rattagan Kajeekul
- Division of Infectious Diseases, Department of Medicine, Maharat Nakhon Ratchasima Hospital, Thailand
| | - Wichai Prayoonwiwat
- Division of Hematology, Department of Medicine, Phramongkutklao Hospital, Thailand
| | - Rungsun Rerknimitr
- Division of Gastroenterology, Department of Medicine, King Chulalongkorn Memorial Hospital, Thai Red Cross Society and Faculty of Medicine, Chulalongkorn University, Thailand
| |
Collapse
|
3
|
Phuensan P, Petsong S, Suwanpimolkul G. 1421. A 5-year Review of Mycobacterium abscessus Susceptibility in a Tertiary Hospital in Thailand. Open Forum Infect Dis 2022. [PMCID: PMC9752637 DOI: 10.1093/ofid/ofac492.1250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Background Mycobacterium abscessus is a common rapid growing mycobacteria (RGM). It causes chronic nodular or cavitary lung disease in adults with bronchiectasis or cystic fibrosis, skin and soft tissue infection following penetrating injury or an unsterile skin procedure. It was also a pathogen of disseminated infection in patients with anti-interferon-gamma autoantibodies. The 2018 clinical and laboratory standards institute (CLSI) guideline suggested that amikacin, cefoxitin, ciprofloxacin, clarithromycin, doxycycline, imipenem, linezolid, meropenem, moxifloxacin, trimethoprim-sulfamethoxazole, tigecycline and tobramycin should be tested against RGM. We aimed to review the antimicrobial susceptibility of this organism in our hospital. Methods We performed a retrospective descriptive review of the minimal inhibitory concentration (MIC) of clinical isolates of M. abscessus from 2013 to 2018. Results We found 267 isolates of M. abscessus. Eighty-four isolates were tested for MICs. Of these, 4 isolates were excluded due to duplication. The remaining 80 isolates were included for analysis. The susceptibility results were as follows. Conclusion To our knowledge, this is the largest report of susceptibility pattern of M. abscessus in Thailand. MICs of cefoxitin and imipenem, which are the recommended intravenous antimicrobials, were high. Most isolates also demonstrated high MICs of doxycycline, linezolid, trimethoprim-sulfamethoxazole, tobramycin, ciprofloxacin and moxifloxacin. In contrast, most of MICs of amikacin and clarithromycin were in susceptible range. These findings may be used to guide the treatment regimen although clinical outcomes of each drug are still to be investigated. Disclosures All Authors: No reported disclosures.
Collapse
Affiliation(s)
- Pawat Phuensan
- King Chulalongkorn Memorial Hospital, Krung Thep, Krung Thep, Thailand
| | | | | |
Collapse
|